Clinical trials: Essential Hypertension.
Hypertension
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.
- Trial name
- ACCELERATE (NCT00797862)
- Testing
- Amlodipine, hydrochlorothiazide, Aliskiren
- Where
- 10 sites in Canada, Costa Rica and 8 more
- Volunteers
- 1,254 people
- Sponsor
- Novartis
Hypertension,Essential
Management of Hypertension Utilizing Trained Community Health Worker in Rural Municipalities of Nepal
The investigators will evaluate whether a system involving Female Community Health Volunteers (FCHVs) and facility-based community health workers (FB-CHWs) of Health Post (Auxiliary Health Workers, Auxiliary Nurse Midwives and…
- Trial name
- MUTU (NCT04521582)
- Testing
- Amlodipine, Lifestyle counselling
- Where
- 2 sites in Nepal
- Volunteers
- 1,428 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hypertension
A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension
The purpose of this study is to compare the efficacy of the Egalet® controlled release formulation to an immediate release Carvedilol tablet.
- Trial name
- NCT00444834
- Testing
- Carvedilol
- Where
- 2 sites in Denmark
- Volunteers
- 14 people
- Sponsor
- Egalet Ltd
Hypertension
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of amlodipine(5mg or 10mg) and losartan (50 mg or 100 mg), amlodipine and losartan alone in reducing blood pressure.
- Trial name
- NCT00942344
- Testing
- Amlodipine plus Losartan, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension
Objective: To evaluate the antihypertensive efficacy of two brands of nifedipine 30mg in patients with hypertension. To assess the safety of 8 weeks of therapy with two brands of nifedipine 30mg in patients with hypertension.
- Trial name
- NCT00173667
- Testing
- Nifedipine 30 mg GITS
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Primary Hypertension
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
- Trial name
- NCT00882947
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Bayer
Essential Hypertension
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of…
- Trial name
- NCT01900171
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone and is related to hypertension…
- Trial name
- NCT03821571
- Testing
- Brain MRI
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
- Trial name
- NCT00846365
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
- Where
- 80 sites in United States, Chile and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Takeda
Hypertension
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696436
- Testing
- Azilsartan medoxomil, Valsartan, Olmesartan
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,291 people
- Sponsor
- Takeda
Child, Only, Essential Hypertension
Juvenile Essential Arterial Hypertension and Vascular Function
The main goal of this study is to investigate the association of the juvenile essential arterial hypertension with systemic micro- and macrovascular reactivity and cerebral vascular function, and to examine the potential impact…
- Trial name
- NCT05109013
- Where
- Croatia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Essential Hypertension, Metabolic Cardiovascular Syndrome
Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2
The purpose of this study is to evaluate the effectiveness of the use of artificial intelligence in home monitoring in patients with uncontrolled arterial hypertension.
- Conditions
- Essential Hypertension, Metabolic Cardiovascular Syndrome, Heart Disease Risk Factors
- Trial name
- Hyper2 (NCT05843682)
- Testing
- Using the Avatr App
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo General Hospital
Essential Hypertension
Safety Study of RMJH-111b to Treat Essential Hypertension
The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension.
- Trial name
- NCT02822222
- Testing
- Magnesium citrate, tribasic anhydrous soft gelatin capsule
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RMJ Holdings, LLC
Essential Hypertension
Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)
Study objective: 1. To evaluate the antihypertensive efficacy, safety and tolerability of the drug after the oral administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential hypertension. 2.
- Trial name
- Fimasartan (NCT00937651)
- Testing
- Fimasartan (BR-A-657•K) 20 mg, Fimasartan (BR-A-657•K) 60 mg, Fimasartan (BR-A-657•K) 180 mg
- Volunteers
- 81 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension…
- Trial name
- NCT06041529
- Testing
- Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
- Where
- 15 sites in South Korea
- Volunteers
- 198 people
- Sponsor
- Yuhan Corporation
Type 2 Diabetes, Systolic Hypertension
Blood Pressure Outcomes With Liraglutide Therapy
Purpose: The purpose of this study is to further study the mechanism by which liraglutide, a relatively new anti-hyperglycemic medication, might lower blood pressure in patients with Type 2 diabetes and high blood pressure.
- Trial name
- BOLT (NCT01755572)
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Mount Sinai Hospital, Canada
Hypertension
Irbesartan and Amlodipine Combination in Controlling Blood Pressure
The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its individual constituents administered as monotherapy…
- Trial name
- I-COMBO (NCT00950066)
- Testing
- IRBESARTAN (SR47436), Amlodipine, Irbesartan / Amlodipine
- Where
- 4 sites in India, Philippines and 2 more
- Volunteers
- 270 people
- Sponsor
- Sanofi
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately…
- Trial name
- NCT05878561
- Testing
- Fimasartan + Indapamide
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Hypertension,Essential
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
- Trial name
- NCT03503773
- Testing
- Alcohol
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 350 people
- Sponsor
- Ablative Solutions, Inc.
Essential Hypertension
Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
The purpose of this study is to compare depressor effect and safety between combination therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive patients.
- Trial name
- ONEAST (NCT00509470)
- Testing
- telmisartan plus hydrochlorothiazide, Amlodipine
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Tokyo University